Need professional-grade analysis? Visit stockanalysis.com
$16.44B
48.00
1,025
N/A
Vimian Group AB (VIMIAN) trades on Nasdaq Stockholm in SEK. The company is classified in the Healthcare sector under the Diagnostics & Research industry. The stock currently trades at SEK30.90, up 1.98% from the previous close.
Over the past year, VIMIAN has traded between a low of SEK24.92 and a high of SEK46.00. The stock has lost 12.8% over this period. It is currently 32.8% below its 52-week high.
Vimian Group AB has a market capitalization of $16.44B, with a price-to-earnings ratio of 48.00.
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through four segments: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name. It also provides procurement and tech-driven operations, such as online marketing, education, and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and surgical and dental products to veterinary clinics and universities, including dentistry and companion animal orthopedics under the Movora brand name. Vimian Group AB (publ) was incorporated in 2020 and is headquartered in Stockholm, Sweden.
Side-by-side comparison against top Healthcare peers.